质子治疗联合同步化疗用于驱动基因阴性局部晚期非小细胞肺癌
回顾性分析62例驱动基因阴性局部晚期非小细胞肺癌患者,质子组25例接受质子治疗联合同步化疗,X线组37例接受X线同步放化疗后序贯1年免疫调节维持治疗。质子组肺和心脏剂量更低,但3级及以上不良事件发生率更高(28.6% vs 4.2%,P<0.05),短期疗效无显著差异,第3年总生存率质子组更优。
要点
- 质子组3级及以上不良事件发生率28.6%,X线组4.2%,差异有统计学意义(P<0.05)。
- 质子组肺剂量(V5、V20、MLD)和心脏剂量(V40、Dmax)低于X线组,差异有统计学意义(P<0.05)。
- 第3年总生存率质子组76.4% vs X线组46.3%,差异有统计学意义(P<0.05)。
核心结论
- 两组前2年无进展生存和总生存无显著统计学差异,质子组在不良反应和第3年总生存方面表现出明显优势。
研究设计与样本
- 回顾性分析62例在筑波大学医院(日本)和青岛大学附属医院(中国)治疗的驱动基因阴性局部晚期非小细胞肺癌患者。
- 质子组25例接受质子治疗联合同步化疗;X线组37例接受X线同步放化疗后序贯1年免疫调节维持治疗。
- 采用RECIST v1.1标准评估疗效,CTCAE v3.0评估不良反应,CB-CHOP方法进行放疗计划和危及器官评估,使用GraphPad Prism v9.0进行统计分析,T检验以P<0.05为差异有统计学意义。
主要发现
- 质子组较X线组CTV和照射野更小,布拉格峰更明显。
- 质子组肺剂量(V5、V20、MLD)和心脏剂量(V40、Dmax)低于X线组,差异有统计学意义(P<0.05);脊髓和食管剂量两组无显著差异(P>0.05)。
- 质子组和X线组3级及以上不良事件发生率分别为28.6%和4.2%,差异有统计学意义(P<0.05);质子组主要为食管炎和肺炎,X线组主要为肺炎、食管炎和心肌炎;两组均未发生放射性脊髓炎或食管气管瘘。
- 质子组和X线组RR分别为68.1%和70.2%(P>0.05),DCR分别为92.2%和86.4%(P>0.05),短期疗效无显著差异。
- 质子组和X线组PFS分别为31.6±3.5个月(95%CI:24.7~38.5)和24.9±1.55个月(95%CI:21.9~27.9)(P>0.05);OS分别为51.6±4.62个月(95%CI:42.5~60.7)和33.1±1.99个月(95%CI:29.2~37.1)(P<0.05)。
临床怎么用
- 作者认为,对于体质虚弱、心肺功能受损、新冠后遗症及存在基础合并症的人群,质子治疗联合同步化疗可能是更合适的治疗模式并提供临床证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To discuss the optimal treatment modality for inoperable locally advanced Non-Small Cell Lung Cancer patients with poor physical status, impaired cardio-pulmonary function, and negative driver genes, and provide clinical evidence. MATERIALS AND METHODS: Retrospective analysis of 62 cases of locally advanced non-small cell lung cancer patients with negative driver genes treated at Tsukuba University Hospital(Japan) and Qingdao University Affiliated Hospital(China).The former received proton therapy with concurrent chemotherapy, referred to as the proton group, with 25 cases included; while the latter underwent X-ray therapy with concurrent chemoradiotherapy followed by 1 year of sequential immunomodulatory maintenance therapy, referred to as the X-ray group, with 37 cases included.The treatment response and adverse reactions were assessed using RECIST v1.1 criteria and CTCAE v3.0, and radiotherapy planning and evaluation of organs at risk were performed using the CB-CHOP method.All data were subjected to statistical analysis using GraphPad Prism v9.0, with a T-test using P < 0.05 considered statistically significant. RESULTS: (1)Target dose distribution: compared to the X-ray group, the proton group exhibited smaller CTV and field sizes, with a more pronounced bragg peak.(2)Organs at risk dose: When comparing the proton group to the X-ray group, lung doses (V5, V20, MLD) and heart doses (V40, Dmax) were lower, with statistical significance (P < 0.05), while spinal cord and esophagus doses showed no significant differences between the two groups (P > 0.05).(3)Treatment-related toxicities: The incidence of grade 3 or higher adverse events in the proton group and X-ray group was 28.6% and 4.2%, respectively, with a statistically significant difference (P < 0.05). In terms of the types of adverse events, the proton group primarily experienced esophagitis and pneumonia, while the X-ray group primarily experienced pneumonia, esophagitis, and myocarditis. Both groups did not experience radiation myelitis or esophagotracheal fistula.(4)Efficacy evaluation: The RR in the proton group and X-ray group was 68.1% and 70.2%, respectively (P > 0.05), and the DCR was 92.2% and 86.4%, respectively (P > 0.05), indicating no significant difference in short-term efficacy between the two treatment modalities.(5)Survival status: The PFS in the proton group and X-ray group was 31.6 ± 3.5 months (95% CI: 24.7 ~ 38.5) and 24.9 ± 1.55 months (95% CI: 21.9 ~ 27.9), respectively (P > 0.05), while the OS was 51.6 ± 4.62 months (95% CI: 42.5 ~ 60.7) and 33.1 ± 1.99 months (95% CI: 29.2 ~ 37.1), respectively (P < 0.05).According to the annual-specific analysis, the PFS rates for the first to third years in both groups were as follows: 100%, 56.1% and 32.5% for the proton group vs. 100%, 54.3% and 26.3% for the X-ray group. No statistical differences were observed at each time point (P > 0.05).The OS rates for the first to third years in both groups were as follows: 100%, 88.2%, 76.4% for the proton group vs. 100%, 91.4%, 46.3% for the X-ray group. There was no significant difference in the first to second years (P > 0.05), but the third year showed a significant difference (P < 0.05). Survival curve graphs also depicted a similar trend. CONCLUSION: There were no significant statistical differences observed between the two groups in terms of PFS and OS within the first two years. However, the proton group demonstrated a clear advantage over the X-ray group in terms of adverse reactions and OS in the third year. This suggests a more suitable treatment modality and clinical evidence for populations with frail health, compromised cardio-pulmonary function, post-COVID-19 sequelae, and underlying comorbidities.
引用
- Jin Y, Shimizu S, Li Y, et al. Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes. Radiat Oncol. 2023. PMID: 37974211. doi:10.1186/s13014-023-02372-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。